A5067044658- Resilience and Mental Health
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Health and Well-being Studies
- Education and experiences of immigrants and refugees
- Migration, Health and Trauma
- Gallbladder and Bile Duct Disorders
- Human Health and Disease
- Cancer-related molecular mechanisms research
- Cancer Diagnosis and Treatment
- Pediatric Hepatobiliary Diseases and Treatments
- Child and Adolescent Psychosocial and Emotional Development
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Gastric Cancer Management and Outcomes
- Neuroblastoma Research and Treatments
- Psychosomatic Disorders and Their Treatments
- Pancreatic and Hepatic Oncology Research
- Animal Nutrition and Health
BC Cancer Agency
2025
University of British Columbia
2024
Allameh Tabataba'i University
2011
Advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) constitute a heterogeneous group of incurable cancers. Lenvatinib is an oral multiple kinase inhibitor that showed activity in grade 1/2 GEP-NENs the phase II TALENT trial, but confirmatory III study has yet to be conducted. To investigate real-world use lenvatinib treating patients with advanced GEP-NENs, we retrospectively analyzed cohort adults unresectable (NENs) from two academic centers Canada who received palliative...
Background: Complete resection followed by adjuvant chemotherapy is the gold standard for patients with localized cholangiocarcinoma (CC) or gallbladder cancer (GBC). However, this not always feasible, and recurrence rates remain high. Objectives: To understand real-world proportions reason treatment failure in resected biliary tract cancers. Design methods: We performed a retrospective population-based review of GBC CC [intrahepatic (IHCC) extrahepatic (EHCC)] between 2005 2019 using BC...
505 Background: Complete resection followed by adjuvant chemotherapy is standard of care for patients with localized cholangiocarcinoma (CC) or gallbladder cancer (GBC) but not always feasible and recurrence rates remain high. Understanding the exact proportions reasons treatment failure important to design new approaches, data regarding this information scarce. Methods: We performed a retrospective population-based review GBC CC (intrahepatic (ICC) extrahepatic (ECC)) resected between...
522 Background: While only accounting for 3% of gastrointestinal malignancies, cholangiocarcinoma (CC) has poor prognosis. New targeted therapies are on the horizon and understanding potential size population eligible such is importance. Contemporary incidence outcomes in Canada have not been studied. Methods: Patients diagnosed with CC between 2005-2019 British Columbia were identified using BC Cancer Registry. Patient characteristics, treatments received collected analyzed. Results: A...
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)